Sitemap
- The Penn Vasculitis Center: A Leader in Vasculitis
- Meet the Team
- Research
- Patient Care
- Donate
- A Randomized Multicenter Study for Isolated Skin Vasculitis (ARAMIS)
- Efficacy and Safety of Study Drug NS-229 in Treatment of Eosinophilic Granulomatosis with Polyangiitis
- Depemokimab Compared with Mepolizumab for Patients with EGPA on Standard of Care Therapy (OCEAN)
- Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
- Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)
- Nasal Microbiome in ANCA Associated Vasculitis and Relapsing Polychondritis (NMB)
- Redefining Autoimmune Diseases Across Rheumatology (RADAR)
- VCRC Genetic Repository One-Time DNA Study
- VCRC Longitudinal Study of Central Nervous System Vasculitis (CNSV)
- VCRC Longitudinal Study of Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- VCRC Longitudinal Study of Relapsing Polychondritis (RP)
- Vessel Wall Enhancement in Giant Cell Arteritis (VEGA)
- Vasculitis Sino-Nasal Indicators for Flares (V-SNIFF)
- A Pragmatic, Open-Label, Two-Stage, Pilot Study of Effectiveness of Immunomodulatory Medications for Patients with Relapsing Polychondritis (PROSPECT)
- A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis